We and others previously identified rare heterozygous mutant alleles in ICP, together with an association with rs2287622 (the p.444A polymorphism) (30, 45, 46).
CRRT should be the first option in these patients because it is associated with less increase in ICP compared with intermittent therapies [ 111].
The serum TBA, CG, ALT and AST was increased in ICP compared with that normal pregnant (Fig. 2e h and Table 2).
Control-BAL exhibited a rapid rise in ICP compared with Cell-BAL, i.e. Control-BAL 154% change from baseline per hour; Cell-BAL 25% change from baseline per hour.
There was no significant reduction in ICP noted with acetazolamide (-19%), amiloride (-11%), furosemide (-1%) or octreotide (-1%).
At high doses, subcutaneous administration of topiramate lowered ICP by 21% (p=0.015) whilst there was no significant reduction in ICP noted with high subcutaneous doses of acetazolamide (-20%), furosemide (-13%), amiloride (-27%) and octreotide (-18%).
Several studies have confirmed a significant decrease in ICP correlated with an increasing serum osmolality [ 97- 99].
The significant increase in ICP coincided with an increase in hypoglycaemic values, which were predominantly observed during the first week.
Nowadays the majority of preterm deliveries are iatrogenic reflecting the practice of elective induction of labour in ICP cases with the aim of reducing the risk of fetal complications.
